To use a self-antigen as a cancer vaccine target, one possibility is to develop enhanced epitopes that are potentially more immunogenic and against which CD8+ T cells specific to the enhanced epitopes may not be deleted or negatively selected [7], [39]. Here, CD8A is linked to cancer.